Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin Effects on FGF23 and Klotho in T2D
NCT02918591Unknown
- Sponsor
- Tel Aviv University
- Start
- Nov 2017
- Primary completion
- Mar 2018
- Modality
- Small Molecules
01
Overview
Open-label trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Tel Aviv University. Primary endpoint: Soluble Klotho at 2 months. Status: unknown.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02918591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02918591.